ERBB2 and breast carcinoma: Here, we proved the feasibility of comparing everolimus plus letrozole NET with FEC NAC in postmenopausal ER-positive, HER2-negative breast cancer patients, and showed that the ultrasound response rate as well as the breast-conserving surgery rate was inspiring in everolimus plus letrozole arm, while the rates were relatively low in FEC chemotherapy arm.